Hairmax Partners with Truemed to Accept FSA/HSA Payments on FDA-Cleared Laser Hair Growth Devices
Boca Raton, FL, June 18, 2025 (GLOBE NEWSWIRE) — Medical-Grade Hair Growth Devices Now Eligible for Pre-Tax Funds
Hairmax, the global leader in laser hair growth technology, is proud to announce a new partnership with Truemed, enabling customers to use FSA (Flexible Spending Account) and HSA (Health Savings Account) funds to purchase eligible Hairmax hair growth medical devices. This collaboration makes Hairmax's full line of Laser Hair Growth solutions—including Laser Caps, Laser Combs, and Laser Band devices—eligible for payment with pre-tax healthcare dollars. This allows customers to save up to 30% or more instantly compared to traditional out-of-pocket spending.
Hairmax laser devices are classified as FDA-cleared medical devices, clinically proven to treat hereditary hair loss and thinning in both men and women. These medical-grade devices use low-level laser therapy (LLLT), a safe, non-invasive, and drug-free treatment that stimulates hair growth, reverses thinning, and increases density and fullness. Backed by decades of clinical research, Hairmax devices are trusted by physicians and hair restoration experts around the world.
'Our partnership with Truemed aligns with our mission to make medically validated hair growth technology accessible to more people,' said Mike Nassar, President of Hairmax. 'Now, customers can invest in their hair health using pre-tax dollars, making it easier and more affordable to take action against hair loss.'
At Truemed, we're excited to broaden our reach through our partnership with Hairmax, a company that shares our commitment to delivering meaningful, health-focused solutions. This collaboration reflects our mission to make health interventions more accessible by enabling HSA/FSA coverage for eligible products that truly improve lives.' – Chantel Hopper, VP of Customer Success & Marketing at Truemed.
In addition to immediate savings, this partnership offers critical year-end benefits. FSA funds typically follow a 'use-it-or-lose-it' policy and must be spent before December 31st. Consumers looking to maximize the value of their remaining 2025 healthcare benefits now have a unique opportunity to invest in clinically proven hair regrowth before their funds expire.
To take advantage of this opportunity, customers can now select the 'Pay with FSA/HSA' option at checkout on Hairmax.com, where Truemed will seamlessly verify eligibility and process the transaction.
About Hairmax
Hairmax is the pioneer and global leader in laser hair growth technology, with over 24 years of innovation and the most FDA clearances in the industry. Hairmax devices are clinically proven and physician-recommended for the treatment of hereditary hair loss and thinning hair. The brand's comprehensive portfolio includes laser devices, hair care, and supplements designed to restore confidence and support a healthy hair growth journey.
About Truemed
About Us blurb: Over $140 billion in HSA/FSA funds sit untouched, with many account holders unaware that their dollars can be spent on more than just prescriptions, doctor's visits, and traditional 'sick-care.' Truemed helps qualified Americans unlock the full potential of these accounts, enabling them to use pre-tax funds on products that help cure, treat, mitigate, and prevent chronic disease, like fitness equipment, supplements, red light therapy, and more. Truemed's curated marketplace and seamless process make it easier to spend smarter and live healthier. Learn more at www.truemed.com .
Learn more at https://hairmax.com/pages/fsa_hsa
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Gilead's twice-yearly HIV prevention injection gets FDA approval
The US Food and Drug Administration has approved Gilead's (GILD) new HIV prevention drug. The drug, lenacapavir, only requires an injection every 6 months. Yahoo Finance Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. What's a big milestone for Gilead Sciences today. The Biotech Giant securing FDA approval for its latest HIV treatment. It's a significant step forward for that company and patients. Gilead also seeing a boost on that news. Our senior health reporter Anjali kamlani joins us now. Au, what is what is the big takeaway for for investors watching all this? Yeah, I think the big takeaway here is that investors have actually been waiting for this approval. They anticipate quick uptake and a high volume of uptake of this drug used as a pre-exposure prophylaxis, you know, prep as the common acronym for those types of drugs. Now, Gilead already has discovy for that, but the difference here is that this new use or new approval for Lenca Paviar, it is a twice yearly injectable. And that is the difference between the regular oral and this new approval. And so that is really going to help boost Gilead's revenues for the year. We know that already Lenca Paviar brings in about $60 million for the company, and they're anticipating that that will get boosted to about $150 to $195 million in revenue for the company for the year. That's the estimate that analysts are expecting with the approval, and they've been waiting for this approval for quite some time. So really good news. You can see that, you know, the stock is benefiting from this right now and is supposed to be a game changer for those patients. There are some questions about whether or not being a twice yearly drug, it will be more expensive than say a daily oral. And so that is something that Gilead has tried to addressing that they plan to have a insurance and non-insurance access point for patients as well. Thanks so much for joining us on this. Appreciate it. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know
Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know originally appeared on Parade. From morning coffee to vitamins, there are plenty of must-have's that help set up a successful daily routine. In fact, according to Johns Hopkins Medicine, a whopping 50% of American adults take a multivitamin, vitamin or mineral supplement regularly. If you happen to be part of that group of consistent vitamin takers though, you'll want to double check your medicine cabinet. Because one lot of B12 vitamins is being voluntarily recalled by Vita Warehouse Corp thanks to the potential presence of undeclared peanuts. 🍳 SIGN UP to get delicious recipes, handy kitchen hacks & fun food news in our daily Pop Kitchen newsletter 🍳 Considering these Welby, Berkley Jensen and VitaGlobe vitamins are also sold by some of the most popular retailers like ALDI and Amazon, there's a good chance shoppers may unknowingly have a bottle. According to a company announcement shared by the U.S. Food and Drug Administration, this recall affects one lot of Aldi Welby B12 Energy Support gummies, Berkely Jensen B12 Vitamin gummies and Vitamin B12 Extra Strength gummies. The FDA warns that 'people with an allergy or severe sensitivity to peanuts run the potential risk of serious or life-threatening allergic reactions,' if they take these no illnesses or allergic reactions have been reported so far. The undeclared peanuts were actually discovered by ALDI. After conducting routine testing per its standard protocol, one of the tests 'indicated a potential presence of a peanut allergen.' While internal testing done by Vita Warehouse Corp. 'verified the absence of peanuts," the recall was issued out of caution. So, how do you know for sure if you have one of the affected vitamins? There are a few key ways. First, these were sold nationwide at ALDI and BJ's in-store. They were also sold online on ALDI's, BJ's and VitaGlobe's websites and on Amazon. Additionally, each product will have an expiration date of October 2026. The company says that each of the affected vitamins have the following UPC codes and Lot numbers. Aldi Welby: clear bottle with white cap, using green, red, and white labeling. UPC Code: 4099100290868 Lot #: 248046601* Berkeley Jensen: clear bottle with white cap, using red and pink labeling. UPC Code: 888670132487 Lot #: 248046601* VitaGlobe: clear bottle with white cap, using white and red labeling. UPC Code: 850005214670 Lot #: 248046601* The Lot codes and expiration dates can all be found printed on the bottom of each bottle. The FDA urges consumers who have a peanut allergy to return or throw away any affected vitamins ASAP. Customers who do return them can expect a full refund from the original store of purchase. Those with further questions can contact Vita Warehouse at 1-855-214-0100 Monday through Friday from 7:30 am to 4 pm Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know first appeared on Parade on Jun 18, 2025 This story was originally reported by Parade on Jun 18, 2025, where it first appeared.
Epoch Times
5 hours ago
- Epoch Times
FDA Approves HIV-Prevention Drug That Nearly Eliminated the Virus's Spread in Clinical Trials
Gilead Sciences announced June 18 that the Food and Drug Administration (FDA) has approved its twice-a-year shot to prevent HIV, with company executives touting the medication as a 'very real opportunity' at ending the HIV epidemic. In a
